Which fecal immunochemical test should I choose?

Journal of Primary Care and Community Health

Volumn 8, Issue 4, 2017, Pages 264-277

  Daly, Jeanette M ^a   Xu, Yinghui ^a   Levy, Barcey T ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Colorectal cancer screening; Fecal immunochemical test; Fecal occult blood test; Health promotion; Proficiency testing programs

Indexed keywords

HEMOGLOBIN;

ADENOMA; CHEMISTRY; COLON POLYP; COLONOSCOPY; COLORECTAL TUMOR; EARLY CANCER DIAGNOSIS; FECES; HUMAN; IMMUNOCHEMISTRY; OCCULT BLOOD; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ADENOMA; COLONIC POLYPS; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; HEMOGLOBINS; HUMANS; IMMUNOCHEMISTRY; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 85041783362     PISSN: 21501319     EISSN: 21501327     Source Type: Journal    
DOI: 10.1177/2150131917705206     Document Type: Article

References (62)

1. Young GP, Symonds EL, Allison JE, et al. Advances in fecal occult blood tests: the FIT revolution. Dig Dis Sci. 2015;60:609-622.
2. Zavoral M, Suchanek S, Majek O, et al. Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol. 2014;20:3825-3834.
3. Daskalakis C, Vernon SW, Sifri R, et al. The effects of test preference, test access, and navigation on colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2014;23:1521-1528.
4. Xu Y, Levy BT, Daly JM, Bergus GR, Dunkelberg JC. Comparison of patient preferences for fecal immunochemical test or colonoscopy using the analytic hierarchy process. BMC Health Serv Res. 2015;15:175.
5. McDonald CA, Burford Y, Yuen AC, Walls RS, Goulston KJ. Immunochemical detection of fecal occult blood. Aust N Z J Med. 1984;14:105-110.
6. Songster CL, Barrows GH, Jarrett DD. Immunochemical detection of fecal occult blood—the fecal smear punch-disc test: a new non-invasive screening test for colorectal cancer. Cancer. 1980;45(5 suppl):1099-1102.
7. Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organ-isers need to know. Gut. 2015;64:1327-1337.
8. Cappell MS. The effect of Nazism on medical progress in gastroenterology: the inefficiency of evil. Dig Dis Sci. 2006;51:1137-1158.
9. Day LW, Bhuket T, Allison J. FIT testing: an overview. Curr Gastroenterol Rep. 2013;15:357.
10. Barrows GH, Burton RM, Jarrett DD, Russell GG, Alford MD, Songster CL. Immunochemical detection of human blood in feces. Am J Clin Pathol. 1978;69:342-346.
11. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol. 2005;100:1393-1403.
12. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570-1595.
13. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104:739-750.
14. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:638-658.
15. US Preventive Services Task Force. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA. 2016;315:2564-2575.
16. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:659-669.
17. Centers for Medicare & Medicaid Services. How to obtain a CLIA certificate of waiver. 2006; https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/downloads/howobtaincertificateofwaiver.pdf. Accessed July 23, 2015.
18. Centers for Medicare & Medicaid Services. Clinical laboratory improvement amendments (CLIA). 2015; https://www. cms.gov/Regulations-and-Guidance/Legislation/CLIA/index. html?redirect=/clia/. Accessed August 13, 2015.
19. Daly JM, Bay CP, Levy BT. Evaluation of fecal immunochemical tests for colorectal cancer screening. J Prim Care Community Health. 2013;4:245-250.
20. College of American Pathologists. Surveys 2014 CM-A Clinical Microscopy Participant Summary. Northfield, IL: College of American Pathologists; 2014.
21. Center for Medicare & Medicaid Services. Clinical laboratory improvement amendments (CLIA) proficiency testing Dos and Don’ts. 2008; https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/downloads/CLIAbrochure8. pdf. Accessed July 23, 2015.
22. Huang Y, Li Q, Ge W, et al. Optimizing sampling device for the fecal immunochemical test increases colonoscopy yields in colorectal cancer screening. Eur J Cancer Prev. 2016;25:115-122.
23. Greenberg PD, Bertario L, Gnauck R, et al. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol. 2000;95:1331-1338.
24. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462-1470.
25. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013;49:3049-3054.
26. Brenner H, Haug U, Hundt S. Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. Int J Cancer. 2010;127:1643-1649.
27. Chiu HM, Lee YC, Tu CH, et al. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol. 2013;11:832-838.e1-2.
28. Crouse AL, De Koning L, Sadrzadeh SM, Naugler C. Sensitivity and specificity of community fecal immunotesting screening for colorectal carcinoma in a high-risk Canadian population. Arch Pathol Lab Med. 2015;139:1441-1445.
29. de Wijkerslooth TR, Stoop EM, Bossuyt PM, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 2012;107:1570-1578.
30. Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol. 2010;105:682-690.
31. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009;150:162-169.
32. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244-255.
33. Levy BT, Bay C, Xu Y, et al. Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy. J Med Screen. 2014;21:133-143.
34. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422-428.
35. Nakama H, Yamamoto M, Kamijo N, et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology. 1999;46:228-231.
36. Nakazato M, Yamano H, Matsushita H, et al. Immunologic fecal occult blood test for colorectal cancer screening. Japan Med Assoc J. 2006;49:203-207.
37. Ng SC, Ching JY, Chan V, et al. Diagnostic accuracy of faecal immunochemical test for screening individuals with a family history of colorectal cancer. Aliment Pharmacol Ther. 2013;38:835-841.
38. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010;105:2017-2025.
39. Rozen P, Comaneshter D, Levi Z, et al. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer. 2010;116: 2115-2125.
40. Rozen P, Knaani J, Samuel Z. Comparative screening with a sensitive guaiac and specific immunochemical occult blood test in an endoscopic study. Cancer. 2000;89:46-52.
41. Rozen P, Knaani J, Samuel Z. Performance characteristics and comparison of two immunochemical and two guaiac fecal occult blood screening tests for colorectal neoplasia. Dig Dis Sci. 1997;42:2064-2071.
42. Rozen P, Levi Z, Hazazi R, et al. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther. 2009;29:906-917.
43. Sohn DK, Jeong SY, Choi HS, et al. Single immunochemical fecal occult blood test for detection of colorectal neoplasia. Cancer Res Treat. 2005;37:20-23.
44. Wong CK, Fedorak RN, Prosser CI, Stewart ME, van Zanten SV, Sadowski DC. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis. 2012;27:1657-1664.
45. Wong MC, Ching JY, Chan VC, et al. Factors associated with false-positive and false-negative fecal immunochemical test results for colorectal cancer screening. Gastrointest Endosc. 2015;81:596-607.
46. Wong MC, Ching JY, Chan VC, et al. Diagnostic accuracy of a qualitative fecal immunochemical test varies with location of neoplasia but not number of specimens. Clin Gastroenterol Hepatol. 2015;13:1472-1479.
47. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;371:187-188.
48. Agresti A, Coull BA. Approximate is better than exact for interval estimation of binomial proportions. Am Stat. 1998;52:119-126.
49. Centers for Medicare & Medicaid Services. Decision memo for screening immunoassay fecal-occult blood test (CAG-00180N). 2003. https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=87&ver= 13&NcaName=Screening+Immunoassay+Fecal-Occult+Blo od+Test&SearchType=Advanced&CoverageSelection=Bot h&NCSelection=NCA%7CCAL%7CNCD%7CMEDCAC% 7CTA%7CMCD&bc=AAAAAAAACAAAAA%3D%3D&. Accessed July 28, 2015.
50. van Rossum LG, van Rijn AF, van Oijen MG, et al. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer. 2009;125: 746-750.
51. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Internal Med. 2014;160:171.
52. Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastrointest Endosc. 2017;85: 2-21.e23.
53. Luthgens K, Albert S, Brenner H. Diverging detection limits of immunochemical tests for occult blood underline the necessity of standardization and quality assurance. Z Gastroenterol. 2016;54:299-303.
54. Haug U, Becker N. Immunochemical fecal occult blood tests for colorectal cancer screening: point-of-care tests are not tenable for a quality-assured program. Dtsch Med Wochenschr. 2016;141:729-731.
55. Grazzini G, Ventura L, Zappa M, et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut. 2010;59:1511-1515.
56. Cha JM, Lee JI, Joo KR, et al. Performance of the fecal immunochemical test is not decreased by high ambient temperature in the rapid return system. Dig Dis Sci. 2012;57:2178-2183.
57. Allison JE, Fraser CG, Halloran SP, Young GP. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver. 2014;8:117-130.
58. Center for Medicare & Medicaid Services, Division of Laboratory Services. CLIA update—January 2016. 2016; https://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/statupda.pdf. Accessed February 3, 2016.
59. Simon S. Organizations commit to goal of 80% colon cancer testing rate by 2018. 2014 (January 26). https://www.cancer. org/latest-news/organizations-commit-to-goal-of-80-percent-coloncancer-testing-rate-by-2018.html. Accessed January 26, 2016.
60. Rabeneck L, Lansdorp-Vogelaar I. Assessment of a cancer screening program. Best Pract Res Clin Gastroenterol. 2015;29:979-985.
61. Giorgi Rossi P, Vicentini M, Sacchettini C, et al. Impact of screening program on incidence of colorectal cancer: a cohort study in Italy. Am J Gastroenterol. 2015;110:1359-1366.
62. Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;315: 2576-2594.